Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
Other Sizes |
|
ln Vitro |
Neuromedin N is 19 times less powerful than neurotensin, competitively inhibits neurotensin's binding to rat brain synaptic membranes, and is quickly inactivated by brain synaptic peptidase [1]. It boosts efficacy when the peptidase inhibitor bestatin is present and competitively inhibits neurotensin binding to rat brain synaptic membranes [2].
|
---|---|
References |
[1]. Li XM, et al. Neuromedin N is a potent modulator of dopamine D2 receptor agonist binding in rat neostriatal membranes. Neurosci Lett. 1993 Jun 11;155(2):121-4.
[2]. Checler F, et al. Neuromedin N: high affinity interaction with brain neurotensin receptors and rapid inactivation by brain synaptic peptidases. Eur J Pharmacol. 1986 Jul 31;126(3):239-44. |
Molecular Formula |
C38H63N7O8
|
---|---|
Molecular Weight |
745.96
|
Exact Mass |
745.474
|
CAS # |
92169-45-4
|
PubChem CID |
9940301
|
Appearance |
White to off-white solid powder
|
LogP |
4.446
|
Hydrogen Bond Donor Count |
8
|
Hydrogen Bond Acceptor Count |
10
|
Rotatable Bond Count |
22
|
Heavy Atom Count |
53
|
Complexity |
1210
|
Defined Atom Stereocenter Count |
8
|
SMILES |
C(N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(=O)O)CC(C)C)CC1C=CC(O)=CC=1)(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN
|
InChi Key |
RZMLVIHXZGQADB-YLUGYNJDSA-N
|
InChi Code |
InChI=1S/C38H63N7O8/c1-7-23(5)31(36(50)42-29(38(52)53)20-22(3)4)43-34(48)28(21-25-14-16-26(46)17-15-25)41-35(49)30-13-11-19-45(30)37(51)32(24(6)8-2)44-33(47)27(40)12-9-10-18-39/h14-17,22-24,27-32,46H,7-13,18-21,39-40H2,1-6H3,(H,41,49)(H,42,50)(H,43,48)(H,44,47)(H,52,53)/t23-,24-,27-,28-,29-,30-,31-,32-/m0/s1
|
Chemical Name |
(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
|
Synonyms |
KIPYIL; Neuromedin-N; Neuromedin N
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~50 mg/mL (~67.03 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (67.03 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.3406 mL | 6.7028 mL | 13.4055 mL | |
5 mM | 0.2681 mL | 1.3406 mL | 2.6811 mL | |
10 mM | 0.1341 mL | 0.6703 mL | 1.3406 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.